Bone Mineral Density Changes on Androgen Deprivation Therapy for Prostate Cancer and Response to Antiresorptive Therapy

Prostate Cancer and Prostatic Diseases - United Kingdom
doi 10.1038/sj.pcan.4500846
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Androgen Deprivation Therapy for Prostate Cancer

2017English

Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia

BJU International
Urology
2019English

Reimbursement Cuts and Changes in Urologist Use of Androgen Deprivation Therapy for Prostate Cancer

BMC Urology
MedicineReproductive MedicineUrology
2015English

Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Cardiovascular and Metabolic Effects of Androgen-Deprivation Therapy for Prostate Cancer

Journal of Oncology Practice
Health PolicyOncology
2018English

A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy

Clinical Genitourinary Cancer
OncologyUrology
2013English

Adaptive Phenotype Drives Resistance to Androgen Deprivation Therapy in Prostate Cancer

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2017English

Androgen Deprivation Therapy as Backbone Therapy in the Management of Prostate Cancer

OncoTargets and Therapy
OncologyPharmacology
2016English

Modulation of the Immune Response to Androgen Deprivation and Radiation Therapy for the Treatment of Prostate Cancer

2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy